Published in Cancer Weekly, November 28th, 2000
Released at the 11th U.S. National Cancer Institute (NCI)-EORTC-AACR Symposium on New Drugs in Cancer Therapy in Amsterdam, The Netherlands, the results showed that 10 of the 53 patients enrolled in the study achieved six-month survival, the primary endpoint for the trial. Equally important, two patients demonstrated objective responses: one patient...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.